Futura Medical's MED3000 on Track for US FDA Approval After Positive Study Results
31 Agosto 2022 - 04:01AM
Dow Jones News
By Kyle Morris
Futura Medical PLC said Wednesday that a study of its MED3000
product has returned highly positive results and that it remains on
track to obtain U.S. FDA marketing authorization.
The London-listed company said the FM71 Phase 3 study of MED3000
for the treatment of erectile dysfunction achieved all primary and
secondary endpoints and was in line with data from a previous Phase
3 study.
Marketing authorization in the U.S. for MED3000 remains on
course for the first quarter of 2023, it said.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
August 31, 2022 02:46 ET (06:46 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Futura Medical (LSE:FUM)
Gráfico Histórico do Ativo
De Mai 2023 até Jun 2023
Futura Medical (LSE:FUM)
Gráfico Histórico do Ativo
De Jun 2022 até Jun 2023
